The lipid amidase NAAA as a therapeutic target for Alzheimer's disease
脂质酰胺酶 NAAA 作为阿尔茨海默病的治疗靶点
基本信息
- 批准号:10118584
- 负责人:
- 金额:$ 232.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcidsAddressAffectAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAnimal ExperimentsAnimal ModelAnti-Inflammatory AgentsAttenuatedBehavioralBiologicalBlood - brain barrier anatomyBrainChronicCysteineDiseaseDisease MarkerDisease ProgressionEnergy MetabolismEnzymesExcisionFunctional disorderGeneticGenetic TranscriptionGoalsHydrolaseImmuneImpaired cognitionInflammationLate Onset Alzheimer DiseaseLipid BiochemistryLipidsMedical ResearchModelingMolecularMorphologyMultiple SclerosisMusNatural ImmunityNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronsNuclear ReceptorsPPAR alphaPalmitatesParkinson DiseasePathogenesisPersonsPharmaceutical PreparationsPharmacologyProcessResearchRoleSenile PlaquesSeriesSeveritiesSignal TransductionSymptomsTestingTranscription CoactivatorUnited Statesage relatedamidasebaseeffective therapyenergy balanceenzyme activityexperimental studyinhibitor/antagonistinnovationmolecular targeted therapiesmouse modelnovelpalmidrolprotective effectsingle-cell RNA sequencingtau Proteinstherapeutic target
项目摘要
PROJECT SUMMARY
Current therapies do not alter the course of Alzheimer's disease (AD), a devastating neurodegenerative
illness that affects 5.8 million people in the United States and 44 million people worldwide. Thus, an urgent
goal for research is to identify points of control for neurodegeneration, which may be targeted to slow down
AD progression. In this application, we propose to test the hypothesis that the enzyme N-Acylethanolamine
Acid Amidase (NAAA) is one such focal point. NAAA is a lysosomal lipid hydrolase that converts
palmitoylethanolamide (PEA) into palmitate. PEA is an endogenous agonist of the neuroprotective nuclear
receptor PPAR-α, whereas palmitate promotes neurodegeneration by suppressing the transcription co-
activator PGC1α, a key regulator of neuronal energy metabolism and survival. Preliminary experiments have
shown that NAAA transcription is abnormally elevated in persons with sporadic AD and in various animal
models of neurodegeneration, including the 5xfAD model of AD. In the same models, we found that
pharmacological NAAA inhibition and/or genetic NAAA deletion exert marked protective effects. Based on
these results, we hypothesize that dysfunctions in NAAA-regulated lipid signaling may be critically
involved in the pathogenesis of AD. We have three specific aims. Aim 1. Characterize NAAA-regulated
lipid signaling in mouse models of AD. Using 5xfAD and Tau P301S mice, two mouse lines that capture
distinct aspects of AD pathology, we will identify age-dependent, regionally selective changes in NAAA-
regulated lipid signaling, which might precede and/or accompany neurodegenerative alterations and
cognitive impairment. Aim 2. Determine the impact of pharmacological NAAA inhibition in mouse models of
AD. We will assess the impact of chronic administration of the compounds ARN19702 and ARN16186 – two
brain-permeant NAAA inhibitors discovered by our team – on molecular, morphological and behavioral
markers of disease progression in 5xfAD and Tau P301S mice. Aim 3. Determine the impact of genetic
NAAA deletion in mouse models of AD. Using our conditional NAAA-/- mice, we will generate NAAA-
deficient 5xfAD and Tau P301S mice to evaluate the impact of NAAA deletion on disease progression. In
Aims 2 and 3, we will also explore molecular and cellular substrates for the effects of NAAA
inhibition/deletion using single-cell RNA sequencing. The proposed studies will elucidate the functional roles
of NAAA-regulated lipid signaling in the pathogenesis of AD and, if our hypothesis is verified, will validate
NAAA as a novel molecular target for the treatment of this disorder.
项目摘要
目前的治疗方法不能改变阿尔茨海默病(AD)的病程,AD是一种破坏性的神经退行性疾病,
这种疾病影响了美国580万人和全世界4400万人。因此,紧急
研究的目标是确定神经变性的控制点,这可能是有针对性的减缓
AD进展。在这个应用中,我们提出测试的假设,酶N-酰基乙醇胺
酸性酰胺酶(NAAA)就是其中的一个焦点。NAAA是一种溶酶体脂质水解酶,可转化
棕榈酰乙醇酰胺(PEA)转化为棕榈酸酯。PEA是一种内源性神经保护性核受体激动剂,
受体PPAR-α,而棕榈酸酯通过抑制转录共-
PGC 1 α是神经元能量代谢和存活的关键调节因子。初步实验已经
表明散发性AD患者和各种动物的NAAA转录异常升高
神经变性模型,包括AD的5xfAD模型。在相同的模型中,我们发现,
药理学NAAA抑制和/或遗传NAAA缺失发挥显著的保护作用。基于
根据这些结果,我们推测NAA调节的脂质信号传导功能障碍可能是
参与AD的发病机制。我们有三个具体目标。目标1.表征NAAA调节的
AD小鼠模型中的脂质信号传导。使用5xfAD和Tau P301 S小鼠,两个小鼠系,其捕获
AD病理学的不同方面,我们将确定NAAA的年龄依赖性,区域选择性变化,
调节的脂质信号传导,其可能先于和/或伴随神经退行性改变,
认知障碍目标2.确定药理学NAAA抑制在小鼠模型中的影响,
AD.我们将评估长期施用化合物ARN 19702和ARN 16186的影响,
我们的团队发现的脑渗透性NAAA抑制剂-分子,形态和行为
在5xfAD和Tau P301 S小鼠中的疾病进展标志物。目标3.确定基因的影响
AD小鼠模型中的NAAA缺失。使用我们的条件性NAAA-/-小鼠,我们将产生NAAA-
用5xfAD缺陷型和Tau P301 S小鼠来评估NAAA缺失对疾病进展的影响。在
目标2和3,我们还将探索NAAA作用的分子和细胞底物
使用单细胞RNA测序检测抑制/缺失。拟议的研究将阐明
在AD的发病机制中,NAAA调节的脂质信号传导,如果我们的假设得到证实,
NAAA作为治疗这种疾病的新的分子靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kim Green其他文献
Kim Green的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kim Green', 18)}}的其他基金
Neuroimmunology Training Program at the University of California, Irvine
加州大学欧文分校神经免疫学培训项目
- 批准号:
10411051 - 财政年份:2022
- 资助金额:
$ 232.86万 - 项目类别:
Cell-type-specific neural circuit connectomes in the mouse models of aging and Alzheimer's disease
衰老和阿尔茨海默病小鼠模型中的细胞类型特异性神经回路连接组
- 批准号:
10620788 - 财政年份:2022
- 资助金额:
$ 232.86万 - 项目类别:
Cell-type-specific neural circuit connectomes in the mouse models of aging and Alzheimer's disease
衰老和阿尔茨海默病小鼠模型中的细胞类型特异性神经回路连接组
- 批准号:
10430810 - 财政年份:2022
- 资助金额:
$ 232.86万 - 项目类别:
Neuroimmunology Training Program at the University of California, Irvine
加州大学欧文分校神经免疫学培训项目
- 批准号:
10630973 - 财政年份:2022
- 资助金额:
$ 232.86万 - 项目类别:
Disease Model Development and Phenotyping Project
疾病模型开发和表型分析项目
- 批准号:
10592223 - 财政年份:2017
- 资助金额:
$ 232.86万 - 项目类别:
Disease Model Development and Phenotyping Project
疾病模型开发和表型分析项目
- 批准号:
10708166 - 财政年份:2017
- 资助金额:
$ 232.86万 - 项目类别:
Origins, properties, and therapeutic potential of cells that repopulate the microglia-depleted adult brain
重新填充小胶质细胞耗尽的成人大脑的细胞的起源、特性和治疗潜力
- 批准号:
10554378 - 财政年份:2014
- 资助金额:
$ 232.86万 - 项目类别:
Origins, properties, and therapeutic potential of cells that repopulate the micro
重新填充微细胞的起源、特性和治疗潜力
- 批准号:
8695963 - 财政年份:2014
- 资助金额:
$ 232.86万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 232.86万 - 项目类别:
Research Grant